Cargando…
Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact
Spasticity is a velocity-dependent increase in muscle tone that has a negative effect on quality of life and hinders the ability of others to provide care. In children, most cases are caused by cerebral palsy. Traditionally, many children are treated with surgery, sometimes performed before their li...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374189/ https://www.ncbi.nlm.nih.gov/pubmed/37499087 http://dx.doi.org/10.1097/MD.0000000000032363 |
_version_ | 1785078723567943680 |
---|---|
author | Gormley, Mark Chambers, Henry G. Kim, Heakyung Leon, Judith Dimitrova, Rozalina Brin, Mitchell F. |
author_facet | Gormley, Mark Chambers, Henry G. Kim, Heakyung Leon, Judith Dimitrova, Rozalina Brin, Mitchell F. |
author_sort | Gormley, Mark |
collection | PubMed |
description | Spasticity is a velocity-dependent increase in muscle tone that has a negative effect on quality of life and hinders the ability of others to provide care. In children, most cases are caused by cerebral palsy. Traditionally, many children are treated with surgery, sometimes performed before their limbs had grown sufficiently to permit long-term success. Nonsurgical treatment comprises oral pharmacological options, but their efficacy is limited and side effects such as drowsiness and decreased short-term memory are common; nerve block procedures can cause painful dysesthesias and muscle scarring. OnabotulinumtoxinA was first approved for the treatment of pediatric lower limb spasticity in Europe in the 1990s and is now licensed for use in pediatric patients in over 80 countries worldwide, based on a large body of clinical evidence demonstrating its efficacy and safety. In 2019 the U.S. Food and Drug Administration approved onabotulinumtoxinA for the treatment of pediatric patients with upper or lower limb spasticity. This approval represents 3 decades of work to refine the dose, measurements, patient selection, and muscle selection. The availability of onabotulinumtoxinA as a treatment for pediatric spasticity can have a substantial impact on a patient’s quality of life. The use of onabotulinumtoxinA in combination with orthoses and occupational/physical therapy can postpone corrective surgery until growth is nearly complete and minimize the number of corrective surgeries. |
format | Online Article Text |
id | pubmed-10374189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-103741892023-07-28 Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact Gormley, Mark Chambers, Henry G. Kim, Heakyung Leon, Judith Dimitrova, Rozalina Brin, Mitchell F. Medicine (Baltimore) OA Supplement Article Spasticity is a velocity-dependent increase in muscle tone that has a negative effect on quality of life and hinders the ability of others to provide care. In children, most cases are caused by cerebral palsy. Traditionally, many children are treated with surgery, sometimes performed before their limbs had grown sufficiently to permit long-term success. Nonsurgical treatment comprises oral pharmacological options, but their efficacy is limited and side effects such as drowsiness and decreased short-term memory are common; nerve block procedures can cause painful dysesthesias and muscle scarring. OnabotulinumtoxinA was first approved for the treatment of pediatric lower limb spasticity in Europe in the 1990s and is now licensed for use in pediatric patients in over 80 countries worldwide, based on a large body of clinical evidence demonstrating its efficacy and safety. In 2019 the U.S. Food and Drug Administration approved onabotulinumtoxinA for the treatment of pediatric patients with upper or lower limb spasticity. This approval represents 3 decades of work to refine the dose, measurements, patient selection, and muscle selection. The availability of onabotulinumtoxinA as a treatment for pediatric spasticity can have a substantial impact on a patient’s quality of life. The use of onabotulinumtoxinA in combination with orthoses and occupational/physical therapy can postpone corrective surgery until growth is nearly complete and minimize the number of corrective surgeries. Lippincott Williams & Wilkins 2023-07-01 /pmc/articles/PMC10374189/ /pubmed/37499087 http://dx.doi.org/10.1097/MD.0000000000032363 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | OA Supplement Article Gormley, Mark Chambers, Henry G. Kim, Heakyung Leon, Judith Dimitrova, Rozalina Brin, Mitchell F. Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact |
title | Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact |
title_full | Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact |
title_fullStr | Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact |
title_full_unstemmed | Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact |
title_short | Treatment of pediatric spasticity, including children with cerebral palsy, with Botox (onabotulinumtoxinA): Development, insights, and impact |
title_sort | treatment of pediatric spasticity, including children with cerebral palsy, with botox (onabotulinumtoxina): development, insights, and impact |
topic | OA Supplement Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374189/ https://www.ncbi.nlm.nih.gov/pubmed/37499087 http://dx.doi.org/10.1097/MD.0000000000032363 |
work_keys_str_mv | AT gormleymark treatmentofpediatricspasticityincludingchildrenwithcerebralpalsywithbotoxonabotulinumtoxinadevelopmentinsightsandimpact AT chambershenryg treatmentofpediatricspasticityincludingchildrenwithcerebralpalsywithbotoxonabotulinumtoxinadevelopmentinsightsandimpact AT kimheakyung treatmentofpediatricspasticityincludingchildrenwithcerebralpalsywithbotoxonabotulinumtoxinadevelopmentinsightsandimpact AT leonjudith treatmentofpediatricspasticityincludingchildrenwithcerebralpalsywithbotoxonabotulinumtoxinadevelopmentinsightsandimpact AT dimitrovarozalina treatmentofpediatricspasticityincludingchildrenwithcerebralpalsywithbotoxonabotulinumtoxinadevelopmentinsightsandimpact AT brinmitchellf treatmentofpediatricspasticityincludingchildrenwithcerebralpalsywithbotoxonabotulinumtoxinadevelopmentinsightsandimpact |